GT Biopharma to Participate in the H.C. Wainwright Immune Cell Engager Conference on August 17, 2023 August 3, 2023
GT Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update March 30, 2023
GT Biopharma, Inc. Announces $6.5 Million Registered Direct Offering Priced At Premium To Market December 30, 2022
GT Biopharma and Fate Therapeutics Present Preclinical Data Highlighting Novel Dual Antigen Targeting Approach For The Treatment of AML at ASH 2022 December 12, 2022